Key Points
- Insider sale: Cindy Tahl sold 10,589 shares of Fate Therapeutics on January 9 at an average price of $1.06 for $11,224.34, leaving her with 387,081 shares — a reported 2.66% drop in her ownership.
- Company financials: FATE trades near $1.07 with a $123.4M market cap and a negative P/E; the company last reported Q3 EPS of ($0.27) beating estimates and revenue of $1.74M.
- Market view: Analysts have an average rating of "Hold" with a $3.92 consensus price target, and institutional investors own about 97.54% of the stock with several large funds recently increasing positions.
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) insider Cindy Tahl sold 10,589 shares of Fate Therapeutics stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $1.06, for a total value of $11,224.34. Following the completion of the transaction, the insider directly owned 387,081 shares of the company's stock, valued at $410,305.86. This represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Fate Therapeutics Price Performance
FATE opened at $1.07 on Tuesday. The stock has a market capitalization of $123.42 million, a P/E ratio of -0.81 and a beta of 2.22. The company's 50 day simple moving average is $1.05 and its 200-day simple moving average is $1.13. Fate Therapeutics, Inc. has a one year low of $0.66 and a one year high of $1.94.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.63 million. Fate Therapeutics had a negative return on equity of 51.28% and a negative net margin of 2,187.11%. As a group, analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on FATE shares. HC Wainwright upgraded shares of Fate Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price on the stock in a research report on Friday, October 31st. Weiss Ratings restated a "sell (e+)" rating on shares of Fate Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Fate Therapeutics in a research report on Tuesday, November 4th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research note on Monday, October 27th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $3.92.
Get Our Latest Stock Report on Fate Therapeutics
Institutional Investors Weigh In On Fate Therapeutics
Several large investors have recently bought and sold shares of FATE. Vanguard Group Inc. raised its holdings in Fate Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 8,798,491 shares of the biopharmaceutical company's stock worth $11,086,000 after purchasing an additional 31,727 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Fate Therapeutics by 67.8% in the 1st quarter. Acadian Asset Management LLC now owns 2,473,565 shares of the biopharmaceutical company's stock valued at $1,952,000 after buying an additional 999,773 shares during the period. Geode Capital Management LLC increased its position in shares of Fate Therapeutics by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,429,167 shares of the biopharmaceutical company's stock valued at $2,721,000 after buying an additional 159,558 shares in the last quarter. Millennium Management LLC raised its stake in Fate Therapeutics by 9.6% during the 3rd quarter. Millennium Management LLC now owns 963,871 shares of the biopharmaceutical company's stock worth $1,214,000 after buying an additional 84,183 shares during the period. Finally, Two Sigma Investments LP raised its stake in Fate Therapeutics by 294.4% during the 3rd quarter. Two Sigma Investments LP now owns 900,757 shares of the biopharmaceutical company's stock worth $1,135,000 after buying an additional 672,352 shares during the period. Institutional investors own 97.54% of the company's stock.
Fate Therapeutics Company Profile
(
Get Free Report)
Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.
Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
